Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VXA-RSV-f
- Development stage
- Phase 1
- Lead developer
- Vaxart
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
VXA-RSV-f is an investigational oral tablet vaccine developed by Vaxart for the prevention of Respiratory Syncytial Virus (RSV) infection. It utilizes Vaxart's proprietary VAAST (Vector-Adjuvant-Antigen Standardized Technology) platform, which employs a non-replicating adenovirus type 5 (Ad5) vector to deliver the gene for the RSV fusion (F) protein to the intestinal mucosa. The vaccine also incorporates a double-stranded RNA (dsRNA) adjuvant that acts as a Toll-like receptor 3 (TLR3) agonist to enhance the mucosal and systemic immune response. By targeting the gut-associated lymphoid tissue (GALT), VXA-RSV-f aims to induce potent mucosal immunity (IgA) in the respiratory tract, as well as systemic neutralizing antibodies and T-cell responses, providing a more convenient and potentially more effective alternative to injectable RSV vaccines.
- Other names
- Vaxart RSV vaccineOral RSV vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on VXA-RSV-f.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VXA-RSV-f.